font size
Sign inprintPrint
DRUG DEVELOPMENT

Amgen's 15-Year Effort to Build a Blockbuster

Podcast: June 14, 2010

The Burrill Report (June 14, 2010): Amgen's 15-Year Effort to Build a Blockbuster (.MP3,14.8 Mb)

Amgen’s denosumab, its treatment for osteoporosis, has won approval in both Europe and the United States. Marketed under the name Prolia, analysts forecast sales will approach $1 billion in 2011 and EvaluatePharma thinks that could grow to $5.3 billion by 2016. We spoke to Dave Lacey, senior vice president and head of research for Amgen, about the long road travelled to bring Prolia to market, why the discovery and development of new drugs like it remains so difficult, and what other interesting therapies might be working their way through Amgen’s deep pipeline.

[Please login to post comments]

Other recent stories